Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 4/20 | 0.38 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.38 |
| ▸ | CA2 | P00918 | 3/20 | 0.38 |
| ▸ | CA9 | Q16790 | 3/20 | 0.38 |
| ▸ | MMP2 | P08253 | 2/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.36 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | CNR2 | P34972 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22390662 | 1.00 | LMNA (0.41) | LMNAPPARAPPARGCA1CA2 | |
| SCHEMBL22390640 | 0.89 | SMN1; SMN2 (0.47) | LMNAPPARAHTTSMN1; SMN2FOLH1 | |
| SCHEMBL22390643 | 0.89 | SMN1; SMN2 (0.47) | LMNAPPARAHTTSMN1; SMN2FOLH1 | |
| SCHEMBL30220168 | 0.83 | PPARA (0.52) | LMNAPPARAPPARG | |
| SCHEMBL22390749 | 0.82 | SLC1A3 (0.41) | HTTSMN1; SMN2FOLH1 | |
| SCHEMBL22390748 | 0.82 | SLC1A3 (0.41) | HTTSMN1; SMN2FOLH1 | |
| SCHEMBL22390629 | 0.79 | CASP3 (0.47) | — | |
| SCHEMBL22390630 | 0.79 | CASP3 (0.47) | — | |
| SCHEMBL22390783 | 0.76 | FOLH1 (0.46) | LMNAPPARAHTTSMN1; SMN2FOLH1 | |
| SCHEMBL22390782 | 0.76 | FOLH1 (0.46) | LMNAPPARAHTTSMN1; SMN2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2023-08-10 | — | — | US | disclosed |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | HISTOGEN, INC. (US) | 2023-03-07 | — | — | US | disclosed |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | NOBO MEDICINE INC. (KR) | 2020-09-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250067-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | LMNA 93/4885PPARA 3631/4885PPARG 3105/4885 |
| US-20200283396-A1 | CASPASE INHIBITORS AND METHODS OF USE THEREOF | CASP1, CASP3, CASP7 | LMNA 93/4885PPARA 3631/4885PPARG 3105/4885 |
| US-11597703-B2 | Caspase inhibitors and methods of use thereof | CASP1, CASP3, CASP7 | LMNA 93/4885PPARA 3631/4885PPARG 3105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.